Main points of investment
Yasheng Pharmaceutical (Ascentage Pharma), a leading innovative molecular drug development company, is a global mid-clinical biomedical technology company specializing in developing innovative treatments for cancer, hepatitis B virus and aging-related diseases. The company was founded in 2009. The founders of the company, Dr. Yang Dajun, Dr. Guo Ming and Dr. Wang Shaomeng, are all recognized experts of the National Thousand talents Plan. The company's senior management team has extensive experience and expertise in drug discovery and development, clinical trials, FDA and CNDA regulatory issues, and intellectual property and licensing management. Since its inception, the company has been favored by many professional venture capital institutions and industrial capital in the industry, raising more than US $200 million and valuing C at a valuation of US $780 million.
The potential market for oncology drugs is vast, and molecular targeted therapy may become the mainstream in the future: the global anti-cancer drug market is expected to grow from US $110.6 billion in 2017 to US $406.8 billion in 2030, mainly driven by innovative targeted therapy. With increasing regulatory support for the introduction of innovative anti-cancer drugs at home and abroad, China's cancer market is expected to grow from US $20.6 billion in 2017 to US $96.8 billion in 2030.
It is expected that by 2030, the overall permeability of small molecular target drugs will further increase and become the most important means of cancer treatment. Targeted small molecule therapy for apoptosis is expected to expand from US $100 million in 2017 to US $36.3 billion in 2030. The market for tyrosine kinase inhibitors (TKI) is expected to expand from US $20.2 billion in 2017 to US $68.6 billion in 2030.
Comprehensive molecular targeted drug product line: the company is committed to the research and development of apoptosis target drugs and next generation kinase inhibitors (TKI), leading the world in the discovery and development of small molecule new drugs targeting PPI (protein-protein interaction) in the apoptotic pathway, and is the only company with a targeted drug platform covering 3 key apoptosis pathways. With its expertise in structure-based drug design and innovative drug discovery engines, the company has 7 drug candidates in clinical development, 20 ongoing clinical trials and 16 submitted experimental new drugs worldwide. The company's core products include 2 Bcl-2 inhibitors APG-1252, APG-2575 and 1 tyrosine beauty inhibitor HQP1351, which are currently in phase I/II, phase I and phase II, respectively. Clinical data show that the company's core products show good safety and tolerance compared with existing or under research products, and have the potential to be used as a single preparation and combined use.
Risk hints: the risk of expected significant losses; the risk of delay or failure in product development, clinical trials, regulatory approval and commercialization; third-party dependence risks; intellectual property related risks.